Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert B Campbell

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Anti-Cancer Agents in Medicinal Chemistry|November 15, 2006
Tumor physiology and delivery of nanopharmaceuticalsRobert B Campbell
Biochimica Et Biophysica Acta|January 30, 2007
Development and characterization of magnetic cationic liposomes for targeting tumor microvasculatureSuman Dandamudi, Robert B Campbell
Biochemical and Biophysical Research Communications|March 11, 2014
Delivery of kinesin spindle protein targeting siRNA in solid lipid nanoparticles to cellular models of tumor vasculatureBo Ying, Robert B Campbell
Biomaterials|August 11, 2007
The drug loading, cytotoxicty and tumor vascular targeting characteristics of magnetite in magnetic drug targetingSuman Dandamudi, Robert B Campbell
Nanomedicine : Nanotechnology, Biology, and Medicine|March 11, 2016
Investigating the role of mucin in the delivery of nanoparticles to cellular models of human cancer disease: an in vitro studyMusaed Alkholief, Robert B Campbell
European Journal of Cancer (Oxford, England : 1990)|December 3, 2008
Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumoursAshish V Kalra, Robert B Campbell
Pharmaceutical Research|October 27, 2006
Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: Implications for tumor vascular targetingAshish V Kalra, Robert B Campbell
Methods in Molecular Biology (Clifton, N.J.)|February 3, 2017
Piloting Your Nanovehicle to Overcome Biological BarriersSteven M Richards, Robert B Campbell
Nanomedicine (London, England)|February 13, 2010
Conjugation of bevacizumab to cationic liposomes enhances their tumor-targeting potentialGeoffrey M Kuesters, Robert B Campbell
The Journal of Biological Chemistry|July 15, 2003
Allosteric activation of PTEN phosphatase by phosphatidylinositol 4,5-bisphosphateRobert B Campbell, Fenghua Liu, Alonzo H Ross
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Anti-Cancer Agents in Medicinal Chemistry|November 15, 2006
Tumor physiology and delivery of nanopharmaceuticalsRobert B Campbell
Biochimica Et Biophysica Acta|January 30, 2007
Development and characterization of magnetic cationic liposomes for targeting tumor microvasculatureSuman Dandamudi, Robert B Campbell
Biochemical and Biophysical Research Communications|March 11, 2014
Delivery of kinesin spindle protein targeting siRNA in solid lipid nanoparticles to cellular models of tumor vasculatureBo Ying, Robert B Campbell
Biomaterials|August 11, 2007
The drug loading, cytotoxicty and tumor vascular targeting characteristics of magnetite in magnetic drug targetingSuman Dandamudi, Robert B Campbell
Nanomedicine : Nanotechnology, Biology, and Medicine|March 11, 2016
Investigating the role of mucin in the delivery of nanoparticles to cellular models of human cancer disease: an in vitro studyMusaed Alkholief, Robert B Campbell
European Journal of Cancer (Oxford, England : 1990)|December 3, 2008
Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumoursAshish V Kalra, Robert B Campbell
Pharmaceutical Research|October 27, 2006
Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: Implications for tumor vascular targetingAshish V Kalra, Robert B Campbell
Methods in Molecular Biology (Clifton, N.J.)|February 3, 2017
Piloting Your Nanovehicle to Overcome Biological BarriersSteven M Richards, Robert B Campbell
Nanomedicine (London, England)|February 13, 2010
Conjugation of bevacizumab to cationic liposomes enhances their tumor-targeting potentialGeoffrey M Kuesters, Robert B Campbell
The Journal of Biological Chemistry|July 15, 2003
Allosteric activation of PTEN phosphatase by phosphatidylinositol 4,5-bisphosphateRobert B Campbell, Fenghua Liu, Alonzo H Ross
Pageof 3